Kevin Damour serves as Executive at Brooklyn ImmunoTherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Kevin Damour has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jun 28, 2022 involved selling 6,077 shares valued at $3.3K.
Kevin Damour currently holds 11,496 shares of Brooklyn ImmunoTherapeutics, Inc. (BTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kevin Damour has been a net neutral trader of BTX stock. They have purchased $0 and sold $0 worth of shares.
Kevin Damour's most recent insider trade was on Jun 28, 2022, when they sold 6,077 shares at $0.55 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |